IL312037A - Endoxifen for treatment of cancers - Google Patents
Endoxifen for treatment of cancersInfo
- Publication number
- IL312037A IL312037A IL312037A IL31203724A IL312037A IL 312037 A IL312037 A IL 312037A IL 312037 A IL312037 A IL 312037A IL 31203724 A IL31203724 A IL 31203724A IL 312037 A IL312037 A IL 312037A
- Authority
- IL
- Israel
- Prior art keywords
- endoxifen
- cancer
- treatment
- concurrent
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163272869P | 2021-10-28 | 2021-10-28 | |
| PCT/US2022/048061 WO2023076496A1 (en) | 2021-10-28 | 2022-10-27 | Endoxifen for treatment of cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312037A true IL312037A (en) | 2024-06-01 |
Family
ID=86158538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312037A IL312037A (en) | 2021-10-28 | 2022-10-27 | Endoxifen for treatment of cancers |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250041245A1 (https=) |
| EP (1) | EP4422608A4 (https=) |
| JP (1) | JP2024541900A (https=) |
| KR (1) | KR20240093500A (https=) |
| CN (1) | CN118159259A (https=) |
| AU (1) | AU2022378576A1 (https=) |
| CA (1) | CA3232972A1 (https=) |
| IL (1) | IL312037A (https=) |
| MX (1) | MX2024005220A (https=) |
| WO (1) | WO2023076496A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4304574A4 (en) * | 2021-03-11 | 2024-11-20 | Atossa Therapeutics, Inc. | ENDOXIFEN FOR THE TREATMENT OF OVARIAN CANCER |
| CN117338780A (zh) * | 2023-09-21 | 2024-01-05 | 中国人民解放军海军军医大学 | 帕罗西汀在制备抗肿瘤药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013033430A1 (en) * | 2011-09-02 | 2013-03-07 | Wake Forest School Of Medicine | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof |
| ES2769634T3 (es) * | 2011-11-04 | 2020-06-26 | Szewczuk Myron R | Uso de inhibidores de la sialidasa NEU1 en el tratamiento del cáncer |
| DE102015222031A1 (de) * | 2015-11-10 | 2017-05-11 | Robert Bosch Gesellschaft Für Medizinische Forschung Mbh | Synthese von (Z)-Endoxifenhydrochlorid |
| WO2017127442A1 (en) * | 2016-01-18 | 2017-07-27 | The Regents Of The University Of California | Methods for treating cancer with rorgamma inhibitors |
| JP7662204B2 (ja) * | 2019-07-03 | 2025-04-15 | アトッサ・セラピューティクス・インコーポレイテッド | エンドキシフェンの徐放性組成物 |
| JP7792335B2 (ja) * | 2019-12-12 | 2025-12-25 | センティ バイオサイエンシズ インコーポレイテッド | 細胞の調節されたアーマリングのための方法及び組成物 |
| EP4304574A4 (en) * | 2021-03-11 | 2024-11-20 | Atossa Therapeutics, Inc. | ENDOXIFEN FOR THE TREATMENT OF OVARIAN CANCER |
| AU2023260712A1 (en) * | 2022-04-26 | 2024-11-14 | Atossa Therapeutics, Inc. | High dose endoxifen formulations and methods of use |
-
2022
- 2022-10-27 MX MX2024005220A patent/MX2024005220A/es unknown
- 2022-10-27 AU AU2022378576A patent/AU2022378576A1/en active Pending
- 2022-10-27 IL IL312037A patent/IL312037A/en unknown
- 2022-10-27 CN CN202280071316.2A patent/CN118159259A/zh active Pending
- 2022-10-27 WO PCT/US2022/048061 patent/WO2023076496A1/en not_active Ceased
- 2022-10-27 EP EP22888189.2A patent/EP4422608A4/en active Pending
- 2022-10-27 JP JP2024524402A patent/JP2024541900A/ja active Pending
- 2022-10-27 US US18/704,892 patent/US20250041245A1/en active Pending
- 2022-10-27 CA CA3232972A patent/CA3232972A1/en active Pending
- 2022-10-27 KR KR1020247013409A patent/KR20240093500A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4422608A4 (en) | 2025-09-24 |
| WO2023076496A1 (en) | 2023-05-04 |
| JP2024541900A (ja) | 2024-11-13 |
| CA3232972A1 (en) | 2023-05-04 |
| AU2022378576A1 (en) | 2024-03-28 |
| CN118159259A (zh) | 2024-06-07 |
| EP4422608A1 (en) | 2024-09-04 |
| MX2024005220A (es) | 2024-05-16 |
| US20250041245A1 (en) | 2025-02-06 |
| KR20240093500A (ko) | 2024-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020102804A3 (en) | Pharmaceutical combination for treatment of cancer | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| IL312037A (en) | Endoxifen for treatment of cancers | |
| BR112022002609A2 (pt) | Métodos de tratamento de tumores estromais gastrointestinais | |
| EA202092343A1 (ru) | Лечение гнойного гидраденита с использованием ингибиторов jak | |
| JP2018127467A5 (https=) | ||
| WO2009067397A3 (en) | Treatment for solid tumors | |
| IL300151A (en) | Combinations for cancer treatment | |
| NO20053782L (no) | Behandling av kreft med 2-deoksyglukose | |
| WO2021207723A3 (en) | Methods of treating diabetic kidney disease | |
| BR112018070017A2 (pt) | métodos de tratamento de cânceres pediátricos | |
| MX2025003477A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| EP4427738A3 (en) | Dosing protocols and regimens for aminosterol treatment | |
| WO2019118779A3 (en) | Peptides and other agents for treating pain and increasing pain sensitivity | |
| MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
| WO2021011844A3 (en) | Combination cancer therapy agents and methods | |
| WO2023196584A3 (en) | Endocytosis inhibitors and their use for pain treatment | |
| WO2020101790A3 (en) | Methods of using a phenoxypropylamine compound to treat pain | |
| WO2024186883A3 (en) | Compositions and methods for the treatment of human papillomavirus-driven cancers | |
| WO2023107712A8 (en) | SOLUBLE β-GLUCANS FOR INDUCING TRAINED IMMUNITY | |
| WO2023019095A3 (en) | Momelotinib combination therapy | |
| IL307842A (en) | Methods and compositions for treating glioblastoma | |
| UY39593A (es) | Tratamiento para tumores sólidos malignos | |
| FI4003533T3 (fi) | Multifokaalisen syövän hoitomenetelmiä | |
| BR112022001796A2 (pt) | Tratamento focal do câncer de próstata |